Monday, December 30, 2019 1:40:15 PM
Lowfloater EARS breaking out:
Float 2.91
Catalyst
M-201 Healthy volunteers in Q1
Chart set up weekly and daily
Daily
weekly
Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity. Upon completion of the transfers from other Group companies, Zilentin AG shall own all tangible and intangible assets related to the development of tinnitus therapeutics (Keyzilen® / AM-101 as well as early stage projects) and hearing loss therapeutics (Sonsuvi® / AM-111). Zilentin Ltd. is domiciled in Zug, Switzerland.
Float 2.91
Catalyst
M-201 Healthy volunteers in Q1
Chart set up weekly and daily
Daily
weekly
Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity. Upon completion of the transfers from other Group companies, Zilentin AG shall own all tangible and intangible assets related to the development of tinnitus therapeutics (Keyzilen® / AM-101 as well as early stage projects) and hearing loss therapeutics (Sonsuvi® / AM-111). Zilentin Ltd. is domiciled in Zug, Switzerland.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
